Sign in
CTMX Stock Price, Chart, Stats & News
CytomX Therapeutics, Inc.
Save
CytomX Therapeutics, Inc. (CTMX) does not currently pay a dividend.
601.48M
Market cap
–
Current P/E
14.20x
Forward P/E
CTMX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.33% |
Operating margin | -29.35% |
Pretax margin | -22.48% |
Net margin | -22.79% |
Effective tax rate | -1.38% |
ROA | -11.39% |
ROE | -19.77% |
D/E | 0.04x |
Interest coverage ratio | – |
CTMX valuation
P/E | – |
P/S | 10.10x |
P/B | 7.77x |
P/CF | -10.18x |
P/FCF | -10.15x |
P/OCF | -10.18x |
PEG | 0.45x |
EV multiple | -40.12x |
About
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates.
Similar securities
Based on sector and market capitalization
Report issue